wire

# "Science Wire" gibt letzten Meldungen von Forschungsinstitutionen und F&E Unternehmen.
Kategorie


Unternehmen/Institution
ABB | AGROSCOPE | BAFU | CERN | EMPA | EPFL | ETHZ | FHNW | FMI | HSLU | HTWCHUR | I-NET | NOVARTIS | PSI | ROCHE | SBFI | SNF | UNIBAS | UNIBE | UNIFR | UNIGE | UNIL | UNILI | UNINE | UZH | VOGELWARTE | ZHAW |

Novartis

Betriebswissenschaft/VWL - Medizin/Pharmakologie
17.07.2014
Novartis maintained strong innovation momentum in second quarter, while reconfirming full year outlook
Net sales grew 2% in Q2, with core operating leverage across Q2 and H1 Net sales of USD 14.6 billion grew 2% (+2% cc ) in Q2; USD 28.7 billion (+2%, +2% cc) in H1 Strong operating income growth i
Medizin/Pharmakologie
15.07.2014
Novartis to license Google "smart lens" technology
Innovative technology offers potential to transform eye care and further enhance Alcon's leadership in contact lenses and intraocular lenses Agreement is a first step for Novartis to evo
Medizin/Pharmakologie - Biowissenschaften
15.07.2014
Novartis announces collaboration with Banner Alzheimer’s Institute on a pioneering prevention study for Alzheimer’s Disease
Two Novartis anti-amyloid investigational treatments will be studied in people with a genetic risk of developing Alzheimer's Disease (AD) The build-up of amyloid in the brain is believed to be
Medizin/Pharmakologie - Biowissenschaften
09.07.2014
Novartis announces NEJM publication of two phase III studies demonstrating high efficacy of secukinumab (AIN457) in psoriasis patients
Results of two phase III psoriasis studies consistently show rapid, very high skin clearance, sustained efficacy and an acceptable safety profile with secukinumab More than 70% of secukinumab 300 mg patients experienced clear (PASI 100) or almost clear skin (PASI 90) during the first 16 weeks of treatment[ 1] If approved, secukinumab could address a high unmet need for new psoriasis treatments, as up to 50% of patients are dissat
Medizin/Pharmakologie - Betriebswissenschaft/VWL
09.07.2014
Novartis releases 2013 Corporate Responsibility Performance Report using best-in-class reporting standard, increasing transparency
2013 Corporate Responsibility (CR) Performance Report builds on a long history of CR and reporting Report uses new Global Reporting Initiative G4 guidelines, one year ahead of required implem
Medizin/Pharmakologie - Philosophie
08.07.2014
Novartis reinforces its leadership in research with new global guidelines for Investigator Initiated Trials (IITs)
Novartis committed to support ethical clinical research; new global guidelines emphasizing the principles of ethics, governance and transparency Clinical research conducted by qualified independent investigators is an important part of drug discovery and development and can help explore unmet medical needs New guidelines reinforce requirement that no commercial funding, involvement or influence are permitted in any aspect of IITs Basel, July 8, 2014 - Novartis released today new global guidelines for Investigator Initiated Trials (IITs).
Medizin/Pharmakologie - Biowissenschaften
07.07.2014
Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation
Designation supports the advancement of CTL019 to help address the unmet need of patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL) The filing was submitted by the Unive
Medizin/Pharmakologie
30.06.2014
Sandoz joins forces with United Nations to combat a leading cause of child mortality worldwide
Sandoz makes long-term commitment to support UN initiative on child mortality Commitment to UN Every Newborn Action Plan involves development and supply of recommended WHO formulation for treat
Medizin/Pharmakologie - Betriebswissenschaft/VWL
18.06.2014
Novartis emphasizes new focused portfolio at its first Meet Novartis Management investor day
New Novartis focused on three leading businesses with innovation power and global scale Pharmaceuticals building business depth in Dermatology, Heart Failure, Respiratory and Cell Therapy, comple
Medizin/Pharmakologie - Biowissenschaften
17.06.2014
Novartis submits application to the FDA for meningitis B vaccine candidate Bexsero
Submission follows receipt of Breakthrough Therapy designation in April 2014, highlighting unmet need for a licensed vaccine for serogroup B in the US Meningitis B is a rare but aggress
Medizin/Pharmakologie - Veranstaltung
16.06.2014
Novartis Holly Springs facility becomes first US pandemic-ready site licensed by the FDA to produce cell-culture influenza vaccines
Cell-culture technology is a modern alternative to manufacture influenza vaccines without chicken eggs, with potential to rapidly respond to a pandemic Flucelvax , an FDA-approved antibiot
Medizin/Pharmakologie - Umweltwissenschaften/Nachhaltige Entwicklung
10.06.2014
Novartis Foundation for Sustainable Development to work with Netherlands Leprosy Relief to help reduce leprosy transmission
Collaboration to provide evidence on the impact of preventatively treating high risk groups to reduce the transmission of leprosy in several countries across Asia, Africa and Latin America Rese
Medizin/Pharmakologie
03.06.2014
Pivotal Phase III data show polycythemia vera patients on Novartis drug Jakavi achieved significant improvement in disease control
77% of patients on Jakavi (ruxolitinib) vs 20% on best available therapy achieved hematocrit control or spleen reduction, key treatment goals in PV Nearly half of ruxolitinib-treated pati
Medizin/Pharmakologie
02.06.2014
Zykadia(TM) shrank tumors in the majority of patients with ALK+ NSCLC, regardless of prior ALK treatment
Ceritinib achieved overall response rate of 58.5%, with a median progression-free survival of 8.2 months Similar findings were observed in patients who started the study with brain metastase
Medizin/Pharmakologie
02.06.2014
Novartis data at ASCO show LBH589 significantly improved progression-free survival in patients with multiple myeloma
Results show adding LBH589 to bortezomib and dexamethasone significantly improved PFS by 37%, meeting Phase III study primary endpoint Median PFS increased by 4 months (12 months in LBH589 arm versus 8 months in placebo arm) ; effect of LBH589 observed across all patient subgroups Most people with multiple myeloma will relapse or become refractory; if approved, LBH589 will be first in its class of anticancer agents availab
Medizin/Pharmakologie
01.06.2014
Pivotal data for Novartis’ investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma
The study met the primary endpoint with objective response rates of 41.8% and 32.5% respectively in the 200 mg and 800 mg treatment arms , Basal cell carcinoma is the most common form of skin
Medizin/Pharmakologie - Betriebswissenschaft/VWL
01.06.2014
Medizin/Pharmakologie - Betriebswissenschaft/VWL
28.05.2014
World MS Day: Novartis launches 7-Day Challenge to ’Live Like You’ enabling people with MS to better understand their lives with MS
7-Day Challenge integrates wearable technology and social media to track daily activities of people with MS, allowing valuable personal insights to enable change Novartis is collaborating wi
Medizin/Pharmakologie
23.05.2014
Alcon receives positive CHMP opinion for Simbrinza , a new fixed-dose combination medicine to treat patients with glaucoma
Simbrinza reduced intraocular pressure in two Phase III studies by 23%-34%, 25%-37% respectively, providing strong efficacy, sustained control throughout the day Only beta blocker-free,
Medizin/Pharmakologie - Betriebswissenschaft/VWL
23.05.2014
Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure
CHMP confirms negative opinion following re-examination of RLX030 - further evidence is required Novartis aims to resubmit for approval with data from ongoing second Phase 3 study (RELAX-AHF-2) Basel, May 23, 2014 - Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion for the use of RLX030 (serelaxin) in the treatment of acute heart failure (AHF) indicating that further evidence is required for a license to be granted in the EU.
Medizin/Pharmakologie
22.05.2014
Novartis presents key advances in cancer research at ASCO and EHA from four new pivotal studies in lung, blood and skin cancers
Pivotal data in ALK+ NSCLC for Zykadia(TM); recently approved by US FDA, marking fastest oncology approval under Breakthrough Therapy designation First presentation of pivotal data from Phas
Medizin/Pharmakologie
21.05.2014
Novartis announces positive results at ATS for once-daily Ultibro Breezhaler versus combination therapy (tiotropium plus formoterol)
QUANTIFY study met primary endpoint demonstrating non-inferiority of Ultibro Breezhaler vs tiotropium 18 mcg plus formoterol 12 mcg in improving health-related quality of life outcomes ,
Medizin/Pharmakologie - Betriebswissenschaft/VWL
19.05.2014
Novartis announces exclusive agreement to extend leadership in ophthalmology, leveraging novel anti-PGDF therapy Fovista
Novartis acquires exclusive ex-US rights to Fovista from Ophthotech; upfront payment of USD 200 million plus potential future recruitment and other milestone payments; additionally Ophthotech to re
Medizin/Pharmakologie - Betriebswissenschaft/VWL
16.05.2014
FDA issues Complete Response Letter for RLX030 for acute heart failure
Agency states further evidence of the efficacy of RLX030 is required for US approval Second phase III study RELAX-AHF-2 progressing well - Novartis intends to resubmit NDA with additional data when available Basel, May 16, 2014 - Novartis announced today that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RLX030 (serelaxin) for the treatment of acute heart failure (AHF), stating that further evidence on the efficacy of RLX030 is required for a US license to be granted.
Medizin/Pharmakologie
15.05.2014
Novartis settles patent litigation on Gleevec (imatinib mesylate) with Sun Pharma subsidiary
Litigation settlement upholds validity of US patents covering polymorphic forms of Gleevec and permits Sun Pharma subsidiary to launch a generic version on February 1, 2016 Patents are vital
Medizin/Pharmakologie
09.05.2014
Novartis data at ARVO 2014 confirm transformational real world outcomes and highlight the safety profile of Lucentis
LUMINOUS, the largest ongoing trial in medical retina, presented 1-year results on the effectiveness and safety profile of Lucentis in patients with wet AMD COMRADE-B study indicates BRVO patients treated with Lucentis had significantly higher vision gains at month 6 compared with dexamethasone New real-world data demonstrates significant differences in rates of endophthalmitis with aflibercept and Lucentis Basel, May
Medizin/Pharmakologie - Biowissenschaften
05.05.2014
Novartis drug Signifor LAR shows superior efficacy in acromegaly patients
Acromegaly, an endocrine disorder resulting from elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels, is associated with high mortality[1,2] Phase III data show
Medizin/Pharmakologie
30.04.2014
Novartis once-daily Ultibro Breezhaler showed superior efficacy versus Seretide * for COPD patients
Ultibro Breezhaler demonstrated superiority in lung function compared to Seretide Accuhaler * in chronic obstructive pulmonary disease ( COPD) patients with or without exacerbations in the previous year Primary and key secondary objectives met in pivotal Phase III LANTERN study Positive results to be part of the regulatory submission for Ultibro Breezhaler in China later this year Basel, April 3
Medizin/Pharmakologie - Biowissenschaften
30.04.2014
Novartis announces presentation of data at AAN showing Gilenya slowed the rate of brain volume loss in MS patients
MS patients have accelerated brain volume loss (up to 3-5 times faster than people without MS), which is associated with physical & cognitive loss of function Data at AAN showed significantly more Gilenya-treated patients (vs.
Medizin/Pharmakologie - Biowissenschaften
29.04.2014
Novartis gains FDA approval for Zykadia(TM), first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib
Zykadia (ceritinib) demonstrated an overall response rate of 54.6% in patients with ALK+ metastatic NSCLC who have no other treatment option Median duration of response to Zykadia was 7.4 mont
Medizin/Pharmakologie - Biowissenschaften
29.04.2014
CHMP recommends EU label expansion of Novartis’ Gilenya and data at AAN confirm efficacy on pre-treated MS patients
CHMP has recognized Gilenya's favorable benefit/risk profile and recommends EU label expansion to patients not responding to DMTs beyond interferon AAN data: Gilenya reduces relapse rates, new MRI lesion counts, brain volume loss & disability progression in pre-treated MS patients with high disease activity Gilenya is the only oral DMT that is effective across four key measures of MS (relapse rates, MRI lesions, brain volume loss
Medizin/Pharmakologie
25.04.2014
Novartis’ INSTEAD study for Onbrez Breezhaler in patients with moderate COPD meets primary objective
Results confirm non-inferiority of Onbrez Breezhaler (indacaterol) in lung function compared to Seretide * (salmeterol/fluticasone) in the studied population In INSTEAD study, patients with moderate COPD and no exacerbations in the past year were switched from salmeterol/fluticasone to Onbrez Breezhaler Study showed similar symptomatic benefits in terms of shortness of breath and health status in patients treated with Onbrez
Betriebswissenschaft/VWL - Medizin/Pharmakologie
24.04.2014
Novartis delivered solid sales and profit growth in the first quarter of 2014
Net sales of USD 14.0 billion up 1% (+3% cc ) with all divisions contributing to growth (cc); core operating leverage (cc) driven by Pharmaceuticals and lower Corporate costs Operating income of
Medizin/Pharmakologie - Biowissenschaften
23.04.2014
New data at AAN to confirm efficacy of Novartis’ Gilenya across four key measures of MS disease activity, including brain volume loss
Gilenya reduced relapse rates, new MRI lesion counts, brain volume loss and disability progression in previously-treated MS patients with high disease activity Data at AAN showed significantly more Gilenya-treated patients (vs.
Medizin/Pharmakologie - Biowissenschaften
23.04.2014
Novartis and Anne Geddes unveil inspirational eBook featuring meningitis survivors in honor of World Meningitis Day
Protecting Our Tomorrows: Portraits of Meningococcal Disease eBook features 15 survivors from around the world; eBook available for free download on iBooks Approximately 500,000 cases of m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
22.04.2014
Novartis announces portfolio transformation
Acquires GSK oncology products, strengthening Novartis' leading Oncology business with novel therapies and becomes GSK's preferred commercialization partner for its oncology pipeline Combines No
Medizin/Pharmakologie - Betriebswissenschaft/VWL
09.04.2014
Novartis appoints Jeff George as Division Head, Alcon as Kevin Buehler retires; Richard Francis named as new Division Head, Sandoz
Basel, April 9, 2014 - Novartis announced today the appointment of Jeff George as Division Head of Alcon, effective May 1, 2014.
Medizin/Pharmakologie - Biowissenschaften
07.04.2014
Novartis meningitis B vaccine Bexsero receives FDA Breakthrough Therapy designation in the US
The designation highlights the potential of Bexsero to meet the urgent need for a licensed vaccine in the US against unpredictable and devastating meningitis B Bexsero, already approved in Eur
Medizin/Pharmakologie - Betriebswissenschaft/VWL
07.04.2014
Novartis and Malaria No More provide two million antimalarial treatments to children in Zambia
One million antimalarial treatments donated by Novartis, matching one million treatments funded through Malaria No More's Power of One campaign Power of One enables the public to fund malari
Medizin/Pharmakologie - Biowissenschaften
03.04.2014
Novartis data on 19 compounds at AACR highlight strong cancer pipeline across multiple molecular targets and biological pathways
More than 50 abstracts highlight breadth and depth of Novartis Oncology pipeline and ability to test various combinations early to target multiple pathways Data show activity of investigationa
Medizin/Pharmakologie - Betriebswissenschaft/VWL
31.03.2014
PARADIGM-HF trial of Novartis’ LCZ696 for chronic heart failure closes early based on strength of interim results
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
27.03.2014
Novartis to work with FDA on path forward for RLX030 for acute heart failure following Advisory Committee outcome
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m&p
Medizin/Pharmakologie - Betriebswissenschaft/VWL
26.03.2014
Study published in NEJM showed LDK378 demonstrated an overall response rate of 58% in patients with ALK+ NSCLC
Novartis study published in NEJM showed LDK378 demonstrated an overall response rate of 58% in patients with ALK+ NSCLC Data showed investigational treatment LDK378 (ceritinib) also achieved a median progression-free survival of seven months Patients with this type of lung cancer, especially those for whom prior therapies have failed, are in need of new treatment options[1] Data served as the basis for regulatory applic
Medizin/Pharmakologie
22.03.2014
New phase III psoriasis data show rapid, significant skin clearance
New phase III psoriasis data show rapid, significant skin clearance and convenient administration with Novartis' secukinumab (AIN457) Pivotal phase III FEATURE and JUNCTURE studies met primary and pre-specified secondary endpoints, showing high efficacy with convenient pre-filled syringe (PFS) and autoinjector/pen (AI)[1],[2] Patient-reported outcomes from FEATURE and JUNCTURE show high patient satisfaction with secukinumab
Medizin/Pharmakologie - Betriebswissenschaft/VWL
21.03.2014
Novartis announces US FDA approval of Xolair for chronic idiopathic urticaria (CIU)
Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.
Medizin/Pharmakologie - Betriebswissenschaft/VWL
21.03.2014
UK recommends Novartis Bexsero vaccine for inclusion in National Immunisation Programme to help protect against devastating meningitis B
UK recommends Novartis Bexsero vaccine for inclusion in National Immunisation Programme to help protect against devastating meningitis B Following further review of evidence, JCVI recommend
Medizin/Pharmakologie - Betriebswissenschaft/VWL
21.03.2014
Novartis announces start of new secukinumab (AIN457) versus Stelara (ustekinumab) phase IIIb head-to-head psoriasis study at AAD 2014
Novartis announces start of new secukinumab (AIN457) versus Stelara (ustekinumab) phase IIIb head-to-head psoriasis study at AAD 2014 Global phase IIIb head-to-head study of secukinumab versu
Medizin/Pharmakologie - Betriebswissenschaft/VWL
20.03.2014
Novartis introduces Lucentis in state of the art pre-filled syringe
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
19.03.2014
Novartis reports data at EBCC-9 for secondary survival endpoint of Afinitor trial in HR+/HER2- advanced breast cancer
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
13.03.2014
Novartis Bexsero meningitis B vaccine receives clinical recommendation for use in infants and adolescents in Australia
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
07.03.2014
Novartis announces positive Phase III study for Jakavi in patients with rare blood cancer polycythemia vera
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
06.03.2014
Novartis announces Xolair approved in EU as first and only licensed therapy for chronic spontaneous urticaria (CSU) patients unresponsive to antihistamines
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Biowissenschaften
28.02.2014
Novartis marks Rare Disease Day with call for more research to understand and find treatments for rare diseases
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m. 5:00 p.m. EST More information Global Media Relations Eric Althoff Basel, Switzerland +41 61 324 7999 eric.althoff [a] novartis (p) com More information Investor Relations Switzerland investor.relations [a]
Medizin/Pharmakologie - Betriebswissenschaft/VWL
26.02.2014
Novartis extends leadership in clinical trial data transparency, reinforcing its support of clinical research and innovation
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m. 5:00 p.m. EST More information Global Media Relations Eric Althoff Basel, Switzerland +41 61 324 7999 eric.althoff [a] novartis (p) com More information Investor Relations Switzerland investor.relations [a]
Medizin/Pharmakologie - Betriebswissenschaft/VWL
25.02.2014
Novartis shareholders approve all resolutions proposed by Novartis Board of Directors
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
21.02.2014
Novartis shows continued commitment in Japan with Lucentis approval in fourth Japanese indication, diabetic macular edema
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m. 5:00 p.m. EST More information Global Media Relations Eric Althoff Basel, Switzerland +41 61 324 7999 eric.althoff [a] novartis (p) com More information Investor Relations Switzerland investor.relations [a]
Medizin/Pharmakologie - Betriebswissenschaft/VWL
19.02.2014
Novartis investigational compound LDE225 met primary endpoint in pivotal trial for patients with advanced basal cell carcinoma
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
17.02.2014
Novartis expands cancer immunotherapy research program with acquisition of CoStim
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Betriebswissenschaft/VWL - Medizin/Pharmakologie
29.01.2014
Novartis delivers strong sales and innovation in 2013; underlying business performance reinforces growth prospects
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
27.01.2014
Novartis recognized among world’s most sustainable companies in Corporate Knights Global 100
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
24.01.2014
Novartis reports positive opinion from CHMP for Xolair in severe form of skin disease CSU, a debilitating form of hives and chronic itch
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Medizin/Pharmakologie - Betriebswissenschaft/VWL
24.01.2014
Novartis to request re-examination of serelaxin (RLX030) in acute heart failure (AHF) for conditional marketing authorization in EU
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m
Logo Careerjet